MDM2 and B-cell chronic lymphocytic leukemia: Ubiquitin specific protease (USP7), a deubiquitylase that is widely known for its role in negatively regulating p53 function by preventing the autoubiquitination and proteasomal degradation of MDM2 [150,151], also represents a legitimate therapeutic target in CLL.